Ankylosing Spondylitis Clinical Trials

A listing of Ankylosing Spondylitis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 51 clinical trials
featured
Ankylosing Spondylitis Study

It’s Time to Stand Up to Ankylosing Spondylitis! Take Part in Research of an Oral Investigational Medication for Ankylosing Spondylitis If you are still suffering from the pain

  • 204 views
  • 23 Nov, 2020
  • 1 location
featured
Randomized, Double-Blind, Parallel-Group, Multi-center study of secukinumab to compare 300 mg and 150 mg at Week 52 in patients with AS who are randomized to dose escalation after not achieving inactive disease during an initial 16 weeks of open-label tx w/secukinumab 150 mg (ASLeap)

Randomized, Double-Blind, Parallel-Group, Multi-center study of secukinumab to compare 300 mg and 150 mg at Week 52 in patients with AS who are randomized to dose escalation after not achieving inactive disease during an initial 16 weeks of open-label tx w/secukinumab 150 mg (ASLeap)  

secukinumab
  • 120 views
  • 23 Nov, 2020
  • 1 location
featured
A Phase III, randomized, double-blind, placebo-controlled trial in patients with Ankylosing Spondylitis (AS).

A Phase III, randomized, double-blind, placebo-controlled trial in patients with Ankylosing Spondylitis (AS).

  • 1456 views
  • 08 Nov, 2020
  • 1 location
featured
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Study Of The Efficacy And Safety Of tofacitinib In Subjects With Active Ankylosing Spondylitis (AS).

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Study Of The Efficacy And Safety Of tofacitinib In Subjects With Active Ankylosing Spondylitis (AS).  

  • 171 views
  • 23 Nov, 2020
  • 1 location
Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis

The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SHR-1314 in patients with active ankylosing spondylitis

  • 0 views
  • 03 Jul, 2021
  • 1 location
Examination of Radiographic Progression Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis

Ankylosing spondylitis (AS) is a chronic inflammatory disease that involves the sacroiliac joints, axial skeleton, entheses and peripheral joints. Current therapy for AS is mainly NSAIDs

infliximab
NSAID
tumor necrosis factor alpha
anti-tumor necrosis factor therapy
steroidal anti-inflammatory drugs
  • 51 views
  • 07 Nov, 2020
  • 8 locations
Creation of a Prospective Cohort of Healthy and Sick Subjects and of a Collection of Associated Biological Resources for the Study of the Immune System and of Its Genetic and Environmental Determinants.

CoSImmGEn is a protocol set up to respond to the current lack of healthy and sick population cohorts. Biological resources from these cohorts allow researchers to study the immune system and its genetic and environmental determinants. Those cohorts and collections are open not only to the Pasteurian community but also …

  • 0 views
  • 15 Mar, 2021
  • 6 locations
Jaktinib Hydrochloride Tablets In The Treatment of Active Ankylosing Spondylitis

This trial uses a multi-center, randomized, double-blind, placebo, parallel-controlled design, and it is expected that about 105 cases will be enrolled in about 10 sites.

  • 0 views
  • 26 Jan, 2021
  • 1 location
Evaluation of Physical Performance in Ankylosing Spondylitis Patients

Ankylosing spondylitis (AS) can cause serious limitations in individuals' physical performance, as it involves the musculoskeletal system and can cause ankylosis and arthritis in both axial and

  • 0 views
  • 03 Feb, 2021
  • 2 locations
Benefit of Adapted Physical Activity for Patients Suffering From Ankylosing Spondylitis

The current management of Spondylarthritis Ankylosant (SA), according to the recommendations of the HAS (High Authority of Health), must be a multidisciplinary global approach coordinated by the rheumatologist combining a pharmacological aspect (NSAID, analgesics, biotherapy ...) and not pharmacological (physical treatments, educational approaches, social measures ...). The therapeutic aim of …

  • 0 views
  • 23 Jan, 2021
  • 1 location